Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or
microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin …
microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin …
Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS)
SC Woller, SM Stevens, DA Kaplan… - Clinical and applied …, 2016 - journals.sagepub.com
Background: Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized
by thrombosis, pregnancy morbidity, and the presence of characteristic antibodies. Current …
by thrombosis, pregnancy morbidity, and the presence of characteristic antibodies. Current …
Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials
Background The efficacy and safety of direct oral anticoagulants (DOACs) for patients with
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature
V Dufrost, J Risse, S Zuily, D Wahl - Current rheumatology reports, 2016 - Springer
Background The cornerstone of thrombotic antiphospholipid syndrome (APS) patients'
management is to prevent recurrent thrombosis by long-term anticoagulation. Purpose of …
management is to prevent recurrent thrombosis by long-term anticoagulation. Purpose of …
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta …
V Dufrost, J Risse, T Reshetnyak, M Satybaldyeva… - Autoimmunity …, 2018 - Elsevier
Abstract Background Direct oral anticoagulants (DOACs) are widely used for secondary
prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not …
prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not …
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
N Noel, F Dutasta, N Costedoat-Chalumeau… - Autoimmunity …, 2015 - Elsevier
Background Long-term anticoagulation is recommended in antiphospholipid syndrome with
thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K …
thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K …
Trial of rivaroxaban in antiPhospholipid syndrome (TRAPS): two‐year outcomes after the study closure
Abstract Background Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective
randomized, open‐label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban …
randomized, open‐label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban …
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials
V Dufrost, D Wahl, S Zuily - Autoimmunity reviews, 2021 - Elsevier
Background The gold standard for secondary thromboprophylaxis in APS is long term
anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and …
anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and …
Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial
J Ordi-Ros, L Sáez-Comet… - Annals of internal …, 2019 - acpjournals.org
Background: The potential role of new oral anticoagulants in antiphospholipid antibody
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …